Plain-English translation of NCT02883335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This is a registry study, which means researchers are collecting and organizing medical information from people living with multiple sclerosis in the Lorraine region of France. Rather than testing a new medication, this study follows patients over time to understand how the disease develops, what treatments work, and which factors affect how quickly the disease progresses. Your medical records, test results, and treatment information help build a detailed picture of multiple sclerosis in your community.
Multiple sclerosis affects people differently, and doctors need long-term information to better understand the disease and predict how it will progress in individual patients. By collecting this information from many patients over years, researchers can identify patterns and factors that influence outcomes, which helps improve care and treatment decisions for everyone with MS.
You likely qualify if…
You likely don't qualify if…
Once you enroll, your neurologist and other doctors in the Lorraine region will share your medical information with the registry — including test results, MRI scans, treatment details, and how your symptoms change over time. You will be checked in on at least every two years, and the registry will continue to collect updates about your condition, medications, and disease progression. You are not required to do anything beyond your regular medical care; the study team gathers information from your existing medical records and appointments.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France
Sponsor
Central Hospital, Nancy, France
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, University of Lorraine
Enrollment target
~6,000 participants
Started
May 2003
Primary completion
January 2030
Last updated on clinicaltrials.gov in February 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Francis Guillemin, MD, PHD
CHRU Nancy
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.